Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.55 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14411160 | 1.00 | CYP3A4 (0.65) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| SCHEMBL14279284 | 0.86 | ALDH1A1 (0.58) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| SCHEMBL26576389 | 0.84 | HRH4 (0.56) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| SCHEMBL22722177 | 0.84 | HRH4 (0.61) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| SCHEMBL12016013 | 0.84 | HRH4 (0.61) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| SCHEMBL22646239 | 0.81 | HRH3 (0.53) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| SCHEMBL16676578 | 0.80 | HRH3 (0.51) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| SCHEMBL29385058 | 0.80 | CYP3A4 (0.67) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| SCHEMBL1131474 | 0.80 | CYP3A4 (0.67) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| SCHEMBL1624184 | 0.80 | CYP3A4 (0.67) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-3964514-A1 | GINKGOLIDE B DERIVATIVE AND SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Huiling Jinxin (Shanghai) Pharmaceutical Technology Co., Ltd (CN) | 2022-03-09 | — | — | EP | disclosed |
| US-20140243282-A1 | METHODS AND COMPOSITIONS FOR DESIGNING NOVEL CONJUGATE THERAPEUTICS | KALLAM SATISH REDDY (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | CYP3A4 1341/4885SLC7A5 3348/4885ALDH1A1 750/4885 |
| US-20140243282-A1 | METHODS AND COMPOSITIONS FOR DESIGNING NOVEL CONJUGATE THERAPEUTICS | EPHA2, C3AR1, FCGRT | CYP3A4 2057/4885SLC7A5 2497/4885ALDH1A1 593/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CYP3A4 712/4885SLC7A5 2582/4885ALDH1A1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.